Secondary infection with SARS-CoV-2

At present, secondary infection with SARS-CoV-2 has been reported continuously. However, from the clinical observation, compared with the first infection of SARS-CoV-2, most of the people infected with SARS-CoV-2 for the second time feel milder symptoms and have a shorter course of disease, so it is necessary to treat them in time after they are infected.

()

Speaking of symptomatic treatment, can I continue to use yiling lianhua qingwen after secondary infection with the novel coronavirus? The answer is yes. As for why it can, I will explain it to you from two aspects of drug prescription and clinical research.

From the perspective of traditional Chinese medicine (TCM), COVID-19 infection belongs to the "epidemic disease". The prescription of Lianhua Qingwen was based on the drug use experience of TCM against epidemic diseases over two thousand years. The prescription was based on Mazingshigan decoction in Zhang Zhongjing's Shang Han Za bing Lun (Treatise on Cold Pathogenic Za Bing) in the Eastern Han Dynasty, Yinqiao powder in Wu Ju Tong's Wen bing Tiao bian (Treatise on Wen Yin) in the Qing Dynasty, and rhuai rhizoma used in Wu You ke's Wen yi Lun (Treatise on Wen Yi) in the Ming Dynasty. Among them, Maxingshigan decoction has a good effect on cough, body heat, thirst, sore throat and other diseases caused by pathogenic heat in the lung and inverse lung qi. Yinqiao powder has the effect of evacuating external pathogens and solving external symptoms, and it is effective for fever, headache and other symptoms. Rhubarb can relieve the heat of the bowels, dispel the pathogens, and discharge the toxins from the feces. At the same time, it can also prevent the progression of the disease and avoid the aggravation of the disease.

In addition, Patchouli, which can aromatize and moisturize the spleen and stomach, and rhodiola, which can clear the lung and dissipate blood stasis and nourish the vital qi, are also innovatively-added to the recipe of Lianhua Qingwen. Modern pharmacological research has confirmed that rhodiola has the effect of improving the body's ability to tolerate hypoxia and regulate immunity, which is of great help to improve the body's ability to resist disease and recover.

It can be seen that Lianhuaqingwen can not only effectively relieve the symptoms such as fever, chills, muscle aches, nasal congestion and runny nose, headache, dry throat and sore throat caused by SARS-CoV-2 infection, but also reduce the risk of the disease developing into severe or critical illness.

Since the emergence of the COVID-19 epidemic in 2020, Lianhua Qingwen has been widely used in clinical treatment and actively carried out scientific research. Up to now, it has published more than 120 papers, including more than 60 SCI papers, forming a complete evidence system from network pharmacology, in vitro experiments, animal experiments, basic material research, and clinical research.

For example, as early as 2020, a multi-center clinical study involving 23 COVID-19 hospitals confirmed that Lianhua Qingwen had shown a good trend in improving the proportion of chest CT improvement and clinical cure rate in patients with confirmed and suspected COVID-19 infection, and reducing the rate of transfer to severe disease.

However, a recent randomized, double-blind, international multicenter clinical trial conducted by 17 hospitals in four countries (China, Thailand, Vietnam, and the Philippines) has again confirmed that Lianhua Qingwen can significantly improve the clinical symptoms of patients with SARS-CoV-2 infection, shorten the recovery of patients with mild-moderate SARS-CoV-2 infection, and has good safety.

It is worth mentioning that Lianhua Qingwen has also shown a clear improvement effect on the treatment of children infected with COVID-19. A study published in Phytomedicine(impact factor: 6.65) confirmed that the time to nucleic acid clearance was 1 day faster and the total length of hospital stay was 1 day shorter in Lianhua Qingwen group than in control group, and the nucleic acid clearance rate was higher in Lianhua Qingwen group than in control group.

From the prescription to the research evidence, it can be seen that Lianhua Qingwen is effective in dealing with SARS-CoV-2 infection, which is why it has been included in the National Health Commission's "Diagnosis and Treatment Plan for SARS-CoV-2 Infection" and the State Administration of Traditional Chinese Medicine's "Guidelines for Traditional Chinese Medicine Intervention at Home of SARS-CoV-2 Infected People" and other programs. Therefore, whether it is the first Yang or secondary infection, we can rest assured to choose Lianhua Qingwen.